Compare AMBP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBP | PHVS |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Luxembourg | Switzerland |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2021 | 2020 |
| Metric | AMBP | PHVS |
|---|---|---|
| Price | $5.04 | $35.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $4.39 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.6M | 617.5K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.31 | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $20.65 |
| 52 Week High | $5.47 | $38.13 |
| Indicator | AMBP | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 52.36 |
| Support Level | $5.06 | $24.55 |
| Resistance Level | $5.44 | $36.36 |
| Average True Range (ATR) | 0.14 | 1.45 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 19.60 | 43.19 |
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. The geographical segments of the company includes Europe and the Americas. Geographically, the company derives a majority of its revenue from the United States.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.